TTrialPathMatch Me to Trials
← Back to trials
RecruitingHCCHepatocellular Carcinoma

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

Eligible age

18+ yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.

Sponsor: University of Texas Southwestern Medical Center

You may qualify if…

  • ✓ Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.
  • ✓ Adults 18 years old and above

You may not qualify if…

  • ✕ Patients post liver transplantation
  • ✕ Patients with concurrent or prior HCC (LR-5 or biopsy proven)
  • ✕ other liver cancer including cholangiocarcinoma
  • ✕ Patients with any active extra-hepatic malignancy
  • ✕ Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit
  • ✕ Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia

Where it's recruiting

Michigan

Ann Arbor

Texas

Dallas

Source: ClinicalTrials.gov · NCT06184152 · last updated 2026-07-02

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver N · TrialPath